Nivolumab Active Regardless of PD-L1 Expression in Advanced Urothelial Carcinoma

Share this content:
Single-agent treatment with nivolumab provided meaningful clinical benefit for previously treated patients with urothelial carcinoma.
Single-agent treatment with nivolumab provided meaningful clinical benefit for previously treated patients with urothelial carcinoma.

Single-agent treatment with nivolumab provided meaningful clinical benefit for previously treated patients with metastatic or unresectable urothelial carcinoma regardless of PD-L1 expression, according to a study published in The Lancet Oncology.1

Limited treatment options are available for patients with metastatic urothelial carcinoma who progress on or after first-line platinum-containing chemotherapy. Responses to second-line therapy are uncommon.

Nivolumab is a fully humanized IgG4 PD-1 immune checkpoint inhibitor antibody that has demonstrated substantial and durable clinical response with a manageable safety profile among previously treated patients with locally advanced or metastatic urothelial carcinoma who progressed after prior platinum-based chemotherapy.

In this international, phase 2 study (CheckMate 275; ClinicalTrials.gov Identifier: NCT02387996), researchers evaluated the activity and safety of nivolumab monotherapy among patients with metastatic or surgically unresectable urothelial carcinoma who experienced disease progression or recurrence despite previous therapy with at least 1 platinum-based chemotherapy regimen.

Investigators enrolled 270 patients with metastatic or surgically unresectable locally advanced transitional cell carcinoma of the urothelium involving the bladder, urethra, ureter, or renal pelvis. All participants received intravenous nivolumab every 2 weeks until disease progression, unacceptable toxicity, or clinical deterioration.

Median follow-up was 7 months. Nearly 20% (95% CI, 15.0-24.9) of the 265 evaluable patients achieved a confirmed objective response.

Investigators found that 28.4% (95% CI, 18.9-39.5) of the 81 patients with PD-L1 expression of 5% or greater, 23.8% (95% CI, 16.5-32.3) of the 122 patients with PD-L1 expression of 1% or greater, and 16.1% (95% CI, 10.5-23.1) of the 143 patients with PD-L1 expression less than 1% achieved an objective response.

RELATED: Pembrolizumab Demonstrates Anti-tumor Activity, Acceptable Safety Profile in Urothelial Cancer

Eighteen percent of patients experienced grade 3 to 4 treatment-related adverse events, of which the most common were grade 3 fatigue and diarrhea. Three patients died from treatment-related adverse events, including pneumonitis, acute respiratory failure, and cardiovascular failure.

Reference

  1. Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017 Jan 25. doi: 10.1016/S1470-2045(17)30065-7 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters